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Summary We examined the efficacy, optimum dosage and adverse effects of
levetiracetam in two prospective trials in children with epilepsy. In the add-on trial,
67 children between 6 months and 16 years were included. In the mono-therapy trial,
10 children between 4 years and 16 years were included. Levetiracetam was titrated
up to an optimal dosage for every individual patient, depending on efficacy and
tolerability, and reflecting clinical practice. The range of dosages used was between
12 and 62 mg/kg/day, with a median of 33 mg/kg/day. Overall, 20 weeks after the
start of levetiracetam, there was a median seizure reduction of 60% (add-on trial 50%;
mono-therapy trial 81%). Levetiracetamwas equally effective for partial and general-
ized seizures. Side effects were less common in the mono-therapy trial. Tiredness
(7.8%) and aggressiveness (5%) were the most common side effects, and were dose-
related, but were no reason to discontinue levetiracetam. In 25% of the children, a
positive effect was seen on behaviour and/or alertness. This could not be related
directly to seizure control. Overall, these two clinical trials confirm that levetir-
acetam is a broad spectrum anti-epileptic drug with a favourable safety profile. The
positive effect on behaviour needs further quantitative study.
# 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
In recent years, several new drugs have been intro-
duced to treat seizures in adults and children. In the
majority of patients, these drugs suppress epileptic
seizures without causing unacceptable side effects,* Corresponding author. Tel.: +32 163 43 845;
fax: +32 163 43 842.
E-mail address: lieven.lagae@uz.kuleuven.ac.be (L. Lagae).
1059-1311/$ — see front matter # 2004 BEA Trading Ltd. Published
doi:10.1016/j.seizure.2004.10.004as has been shown in the necessary registration
studies (for a review, see Mohanray and Brodie,
2003).1 In childhood epilepsy, seizure control and
favourable safety profile are not the only outcome
parameters that are important in clinical practice.
A major concern is a possible negative effect of
anti-epileptic drugs on cognitive functions in the
developing brain. These issues are not always dealt
with in the registration studies. For clinical prac-
tice, post-registration experience with the newby Elsevier Ltd. All rights reserved.
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indications, best dosage, possible combination
therapies, effect in specific epilepsy syndromes
and previously unrecognized adverse effects.
Levetiracetam is new anti-epileptic drug with
proven efficacy in partial and generalized seizures,
both in adults and children, and with a good safety
profile.2—10 In this prospective clinical study, we
evaluated the effect of levetiracetam in 77 children
with a variety of childhood epilepsy syndromes with
both partial and generalized seizures. Most children
had difficult to treat epilepsy. Besides seizure con-
trol, special attention was paid to the effect of
levetiracetam on behaviour and alertness. Themed-
ication was provided by UCB in 2 ‘investigator-dri-
ven’ clinical studies, so that we could also study the
effect of levetiracetam for non-registered indica-
tions.Methods
The two study protocols were approved by the
Ethical Committee of our University Hospital.
Add-on study
In the add-on study, children >6 months could be
included. In a baseline period of 4 weeks before
inclusion, all patients had at least four seizures that
could be adequately described by the parents or the
care-givers. We used this clinical information to
categorize the predominant seizure type as partial
or generalized, following the ILAE criteria. In
patients with both partial and generalized seizures,
we used the classification ‘mixed’.
Levetiracetam was started at a dosage of 10 mg/
kg/day, given in two equal dosages. Levetiracetam
was increased weekly by 10 mg/kg up to a maximum
of 60 mg/kg/day, depending on efficacy and toler-
ability. Background anti-epileptic drugs were kept
stable for the first 12 weeks of the study.
Mono-therapy trial
In the mono-therapy trial, children >4 years could
be included. In this study, levetiracetam was the
first drug that was administered or was the second
drug that was tried after discontinuing a first, inef-
fective, anti-epileptic drug. Inclusion criteria, clas-
sification of seizure type and levetiracetam dosage
schedule were otherwise the same as in the add-on
trial.
In both studies, children were seen and examined
at inclusion, after 4, 8, 12 and 20 weeks. A struc-
tured data file and questionnaire were used tocollect the necessary data. Patient diaries and
detailed history were used to calculate seizure
frequency as accurately as possible. Overall quality
of life was scored by the parents on a scale from 0 to
10, with 10 being the maximum. Their judgment on
this scale represents a combination of efficacy and
tolerability.
At 20 weeks, or at the last follow-up visit if
levetiracetam was discontinued before 20 weeks,
an analysis of effect and tolerability was performed.
Percentage seizure reduction was calculated for
every child and for the different seizure types.Results
In Table 1, the two study populations are presented.
Sixty-seven and 10 children with a median age of 8
and 9 years were included in the add-on and the
mono-therapy trial respectively. In the add-on trial
there were 18 children below the age of 4 years,
including 6 below the age of 1 year.
In the add-on study, no aetiology for the epilepsy
was found in 26 children. These children presented
with partial (n = 12), myoclonic (n = 7), multifocal
(n = 3) and generalized (n = 4) seizures. In the other
41 children of the add-on group, the aetiology was
variable: West syndrome (2), Lennox—Gastaut syn-
drome (7), cortical malformations (6), tuberous
sclerosis (3), severe myoclonic epilepsy of infancy
(2), acquired brain lesions (9), metabolic disorders
(3), isolated mental retardation and autism (5),
tumour (3), ESES (1). The fact that 85% of the
children in that group were mentally retarded
underlines the severity of their neurological dys-
function. The number of background anti-epileptic
drugs was 2 or more in 76% of the children, indica-
tive of the refractory character of their epilepsy.
In the mono-therapy trial, six children presented
with generalized seizures: two with classical child-
hood absences, two withmyoclonic seizures and two
with tonic/clonic seizures. In the four children with
partial seizures, one child was classified with benign
rolandic epilepsy and two with complex partial
seizures in the context of cerebral palsy. These were
the only two children in that group with mental
retardation.
In both groups, the distribution between general-
ized and partial seizures was comparable.
The range of prescribed levetiracetam dosages
was large: 12—62 mg/kg/day for the total group.
The median dosage in the mono-therapy trial
(29 mg/kg/day) was somewhat, but not statistically,
lower than in the add-on trial (33 mg/kg/day).
The retention rate at 20 weeks was high in both
groups. Overall, 75% (58/77) of the children com-
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Table 1 Clinical characteristics of the two study populations.
Study populations Mono-therapy levetiracetam Add-on levetiracetam Total population
Number of patients 10 67 77
Median age (year) 9 8 9
Age range (year) 4—14 0.5—16 0.5—16
Mental retardation 2 (20%) 57 (85%) 59 (76%)
Predominant seizure type
Generalized seizures 6 (60%) 32 (48%) 38 (49%)
Partial seizures 4 (40%) 31 (46%) 35 (46%)
Mixed seizures 0 (0%) 4 (6%) 4 (5%)
Number of background anti-epileptic drugs
0 10 (100%) 0 (0%) 10 (14%)
1 0 (0%) 16 (24%) 16 (20%)
2 0 (0%) 29 (43%) 29 (38%)
3 0 (0%) 20 (30%) 20 (26%)
4 0 (0%) 2 (3%) 2 (2%)
Levetiracetam dosage
Median (mg/kg/day) 29 33 33
Range (mg/kg/day) 17—47 12—62 12—62
N completed 20 weeks 9 (90%) 49 (73%) 58 (75%)pleted the 20 weeks study period. Levetiracetam
was stopped prematurely because of lack of efficacy
in the 17 of the 19 children. Nine of the 19 children
who did not complete the trial, stopped after visit 3
(8 weeks) and the remaining 10 after visit 4 (12
weeks). The total exposure duration to levetirace-
tam, was 338 months, compared to the theoretical
385 months if every child would have ended the full
trial (77  5 months).Table 2 Efficacy of Levetiracetam in the two study groups
Efficacy Mono-therapy
levetiracetam (n = 10)
Median percent reduction 81%
N patients >50% red 9 (90%)
N seizure free 2 (20%)
N seizure increase 0
Generalized seizures 6
Median percent reduction 83%
n > 50% reduction 5 (83%)
n seizure free 1 (17%)
n seizure increase 0 (0%)
Partial seizures 4
Median percent reduction 75%
n > 50% reduction 4 (100%)
n seizure free 1 (25%)
n seizure increase 0
Mixed seizures 0
Median percent reduction —
n > 50% reduction —
n seizure free —In Table 2, the efficacy of levetiracetam in the two
study groups is shown. In the add-on trial, therewas a
median seizure reduction of 50%. In 33/67 (49%)
children, a seizure reduction of >50% was observed.
Three of the 67 children became seizure free. In the
mono-therapy trial, results were even better. In 9/10
children, there was a seizure reduction of >50% was
found for 9/10 children and the median seizure
reduction was 81%. 2 children became seizure free.
Add-on levetiracetam
(n = 67)
Total population
(n = 77)
50% 60%
33 (49%) 42 (54%)
3 (4.5%) 5 (6%)
10 (15%) 10 (13%)
32 38
50% 50%
14 (44%) 19 (50%)
0 1 (2.5%)
5 (15%) 5 (13%)
31 35
57% 66%
16 (51%) 20 (57%)
2 (6%) 3 (8.5%)
5 (16%) 5 (14%)
4 4
70% 70%
3 (75%) 3 (75%)
1 (25%) 1 (25%)
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Table 3 Adverse effects of Levetiracetam in the two study groups.
Adverse effects,
quality of life
Mono-therapy
levetiracetam (n = 10)
Add-on levetiracetam
(n = 67)
Total population
(n = 77)
No adverse effects 9 (90%) 42 (62%) 49 (64%)
Aggressiveness 0 4 (6%) 4 (5%)
Tiredness 0 6 (9%)a 6 (7.8%)
Anorexia 1 0 (0%) 1 (1.3%)
Headache 0 1 (1.5%) 1 (1.3%)
Stop LEV for side effects 0 2 2
Positive effects
Increased alertness 3 (30%) 18 (27%)b 21 (27%)
Better behaviour 1 (10%) 16 (24%)c 17 (22%)
Overall quality of life n = 10 n = 49 n = 59
Median score 8/10 6/10 7/10
Range score 6—9 0—9 0—9
a 4/6 on LEV >45 mg/kg.
b 7/18 with seizure red <50%.
c 7/16 with seizure red <50%.in that group. Both were previously untreated; one
was diagnosed with childhood absence epilepsy and
the other with benign rolandic epilepsy.
In the add-on group an increase of seizure fre-
quency was observed in 10/67 (15%) children. In
these 10 children, the median increase was 50%,
with a range between 18% and 420%. In 3 of these 10
children, the number of seizures was more than
twice the baseline frequency (200%). No reason
for this phenomenon could be identified in our data:
there was no effect of age, dosage, background anti-
epileptic drugs, seizure type or epilepsy syndrome.
Looking at partial and generalized seizures sepa-
rately, no significant differences could be found (see
Table 2). This was confirmed in a separate analysis
on the efficacy of levetiracetam in the different
epilepsy syndromes: there were no epilepsy syn-
dromes in which levetiracetam had a specific effi-
cacy profile. Also, no combination with a particular
anti-epileptic drug proved to be superior or inferior.
The number of reported adverse effects was very
low in both cohorts and in only two children these
adverse effects were the actual reason to stop the
medication (Table 3). The most frequently reported
adverse effect was ‘tiredness’, or ‘increased sleepi-
ness’ as expressed by some parents. This adverse
effect was seen only in the add-on group and was
related to the levetiracetam dosage. In 4/6 children
with ‘tiredness’, the levetiracetam dosage was
>45 mg/kg/day. In only one child this adverse effect
was the reason to discontinue the medication. In
four other children, the parents reported a change
in behaviour with increased impulsiveness and
aggressiveness. However, this was not a reason to
discontinue the medication. One other child
stopped the medication because of recurrent head-aches. In the mono-therapy trial, anorexia was
reported in one child.
We also systematically asked for possible positive
effects of the medication on alertness and beha-
viour. We could not test this quantitatively in this
study group with many severely retarded children,
and therefore, a structured questionnaire was used
for this purpose. In about 1/4 children there was a
positive effect on alertness and/or behaviour. A
better alertness typically indicated a better verbal
or non-verbal communication between the care-
givers and the child. Better behaviour in most chil-
dren meant that the child could be better handled
and structured. In most cases, the children were
calmer. These positive effects after the introduction
of levetiracetam were not always related to seizure
frequency reduction. In 7/18 children with
increased alertness, there was a seizure reduction
of less than 50%. Also, in 7/16 children with better
behaviour, seizure reduction was less than 50%.
Overall quality of life was expressed on a quanti-
tative scale from 0 to 10. This scale was completed
by 49/67 parents in the add-on group and in 10/10
parents in the mono-therapy trial. The parents were
instructed that a ‘10’ would mean that levetirace-
tam was ‘the wonder medication’ for the child. The
median score was 6 in the add-on group and 8 in the
mono-therapy trial. Range was very large in the add-
on group (0—9), while scores were 6 or higher in the
mono-therapy trial.Discussion and conclusions
This study is based on clinical practice and provides
new insights in the use, efficacy and side effects of
70 L. Lagae et al.levetiracetam in childhood epilepsy. In contrast with
the regulatory studies, we titrated levetiracetam to
an individual optimal dosage and were not limited by
age limit, epilepsy syndromeor seizure type.Ourdata
basically confirm that levetiracetam is a broad spec-
trum anti-epileptic drug with a safe profile.
In our add-on trial, children refractory to ‘first
line’ anti-epileptic drugs were included. Many of
these patients were known with catastrophic epi-
lepsies, such as the Lennox—Gastaut syndrome.
Also, many children were between 6 months and
4 years, an age range for which no systematic data
are available yet. In our smaller mono-therapy trial,
children with more benign epilepsy syndromes were
included. In about 50% of the patients in the add-on
trial, there was a seizure reduction of >50%. These
numbers were significantly higher in the mono-ther-
apy trial, with 90% of the patients showing a seizure
reduction of >50% and 20% becoming seizure free.
Only limited data are available on mono-therapy use
of levetiracetam in children. Ben-Menachem
reported the results of two mono-therapy trials in
adults, showing a good efficacy and safety profile.11
In the study of Cohen, three adult refractory
patients with primary generalized epilepsy became
seizure free on levetiracetam mono-therapy.12
Bello-Espinoza and Roberts successfully used leve-
tiracetam as mono-therapy in three children with
benign rolandic epilepsy.13
Both in the add-on trial and in the mono-therapy
trial, levetiracetam was effective in partial and gen-
eralized seizures. Especially the data for generalized
seizures are interesting since many childhood epilep-
tic syndromes, and especially the catastrophic epi-
lepsies, are characterized by the presence of
generalized seizures. Most previous studies on leve-
tiracetam in childhood epilepsy, were focused on
partial seizures.7—9 In our previous study, we could
show a beneficial effect of levetiracetam on general-
ized and especially on myoclonic seizures.9 This was
also confirmed in the study ofWheless and Ng.8 and in
the review paper by Glauser and Dulac.7
The individual dosages in both groups were very
variable (12—62 mg/kg/day), indicating that a pre-
set dosage of for instance 30—40 mg/kg/day is per-
haps not an optimal solution for the individual
patient. In the mono-therapy trial, for instance,
dosages tended to be lower.
In 15% of the patients of the add-on trial an
increase of the number of seizures was found. Simi-
lar findings were reported in the study of Nakken et
al.14 In their study, this increase was seen most
frequently in mentally retarded patients, in the
beginning of the therapy and on rather high doses.
We could not find a similar explanation for this
phenomenon, although 85% of our patients wereindeed mentally retarded. This increase was not
seen in the last weeks before analysis which could
indicate a tolerance effect. A recent study showed
that there was a sustained effect of levetiracetam in
(adult) patients.15 There was also no relationship
with finale-dosage. It is possible that this increase
may reflect the natural course in these difficult
epilepsy syndromes in non-responsive patients.
We found significantly fewer adverse effects than
in the registration trials, and these few adverse
effects were rarely the reason to stop levetirace-
tam. Adverse effects appeared to be related to
final-dosage, again emphasizing an individualized
approach. Although the sample is small, patients
in the mono-therapy trial did not show any adverse
effect. In a recent study, behavioural problems were
seen in about 7% of the 53 adult patients and were
the main reason for discontinuation.16 Potential risk
factors, the study identified pre-treatment psychia-
tric problems and symptomatic generalized epi-
lepsy. Our study in children actually yields similar
percentages: in 6% of the children in the add-on
study, more aggressive behaviour was noted by the
parents. However, this was not a reason for drug
discontinuation in these children.
In the opinion of many parents the positive effects
on behaviour and especially on alertness were the
most important effect. In 1/4 of the patients, a
positive effect was reported, although these high
numbers might represent a bias, since these effects
were specifically asked for. This positive effect was
also noted by Herranz et al. in their study in 43
children.10 In 34.9% there was an improvement in
social behaviour and in cognitive skills. In the study
of Wheless and Ng, a similar positive effect on cogni-
tion was noted. Themechanism of this positive effect
is difficult to explain. The most obvious reason would
be that increased alertness or better behaviour is
related to seizure control, or perhaps to a decrease
of epileptic EEG abnormalities. The fact that this
positive effect was not directly related to efficacy
in our study, makes this hypothesis less likely as a
major determinant. It remains to be determined
whether levetiracetam has a genuine positive effect
on behavioural parameters. Neuropsychological and
neurophysiological studies are needed to explore this
behavioural/cognitive issue in the use of levetirace-
tam in childhood epilepsy.Acknowledgement
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